Expression and prognostic significance of programmed death protein 1 and programmed death ligand‐1, and cytotoxic T lymphocyte‐associated molecule‐4 in hepatocellular carcinoma
Authors:
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies and causes of death worldwide. In this study, we assessed the correlation between clinicopathologic factors with programmed cell death protein 1 (PD‐1) and programmed cell death ligand‐1 (PD‐L1), and cytotoxic T lymphocyte‐associated molecule‐4 (CTLA‐4) expressions. Furthermore, we analyzed the prognostic significance of these proteins in a subgroup of patients. We retrospectively evaluated the PD‐1, PD‐L1, and CTLA‐4 expressions in 294 HCC tissue microarray samples using immunohistochemistry. PD‐1 and PD‐L1 expressions were significant related to high CD8+ tumor‐infiltrating lymphocytes (TILs) (r = 0.664, p < 0.001 and r = 0.149, p = 0.012). Only high Edmondson–Steiner grade was statistically related to high PD‐1 expression. High PD‐L1 expression was demonstrated as an independent poor prognostic factor for disease‐free survival in addition to previous known factors, size >5 cm and serum albumin ≤3.5 g/dL in high CD8+ TILs group. We have demonstrated that the combined high expression of PD‐L1 and CD8+ TIL is an important prognostic factor related to the immune checkpoint pathway in HCC and furthermore, there is a possibility that it could be used as a predictor of therapeutic response. Also, this result would be helpful in evaluating the applicable group of PD‐1/PD‐L1 blocking agent for HCC patients.Keywords
Funding Information
- Korea University (K1503351)
This publication has 30 references indexed in Scilit:
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α productionJournal of Translational Medicine, 2013
- Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinomaLaboratory Investigation, 2010
- Hepatitis B and hepatocellular carcinoma #Hepatology, 2009
- Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversionHepatology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell CarcinomaClinical Cancer Research, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interactionInternational Journal of Cancer, 2005
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004
- Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4–CD8–) thymocytesInternational Immunology, 1996